Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
Provided By GlobeNewswire
Last update: May 7, 2025
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress.
Read more at globenewswire.com
